Discovery of a piperazine urea based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonist
摘要:
We report the discovery of piperazine urea based compound 1, a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonist. Compound 1 shows anti-obesity efficacy without potentiating erectile activity in the rodent models. (C) 2011 Elsevier Ltd. All rights reserved.
Discovery of a piperazine urea based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonist
摘要:
We report the discovery of piperazine urea based compound 1, a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonist. Compound 1 shows anti-obesity efficacy without potentiating erectile activity in the rodent models. (C) 2011 Elsevier Ltd. All rights reserved.
[EN] PIPERAZINE UREA DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS<br/>[FR] DERIVES D'UREE DE PIPERAZINE UTILISES COMME AGONISTES DES RECEPTEURS DE MELANOCORTINE-4
申请人:MERCK & CO INC
公开号:WO2004024720A1
公开(公告)日:2004-03-25
Certain novel piperazine urea derivatives are agonists of the human melanocortin-4 receptor (MC-4R) and, in particular, are receptor-subtype selective agonists of MC-4R. They are useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity and diabetes.
Discovery of a piperazine urea based compound as a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonist
作者:Qingmei Hong、Raman K. Bakshi、Brenda L. Palucki、Min K. Park、Zhixiong Ye、Shuwen He、Patrick G. Pollard、Iyassu K. Sebhat、Jian Liu、Liangqin Guo、Doreen E. Cashen、William J. Martin、David H. Weinberg、Tanya MacNeil、Rui Tang、Constantin Tamvakopoulos、Qianping Peng、Randy R. Miller、Ralph A. Stearns、Howard Y. Chen、Airu S. Chen、Alison M. Strack、Tung M. Fong、D. Euan MacIntyre、Matthew J. Wyvratt、Ravi P. Nargund
DOI:10.1016/j.bmcl.2011.02.090
日期:2011.4
We report the discovery of piperazine urea based compound 1, a potent, selective, orally bioavailable melanocortin subtype-4 receptor partial agonist. Compound 1 shows anti-obesity efficacy without potentiating erectile activity in the rodent models. (C) 2011 Elsevier Ltd. All rights reserved.